Study summary
Interferon beat phlebotomy alone and may modify the disease
3.05odds ratio for complete blood-count response vs phlebotomy alone
What was tested
A pooled analysis of randomized trials of ropeginterferon alfa-2b, a long-acting interferon, against hydroxyurea or phlebotomy alone, for polycythemia vera.
What they found
- Compared with phlebotomy alone, ropeginterferon improved complete blood-count responses (odds ratio 3.05) and lowered the JAK2 mutation burden.
- Results were similar to hydroxyurea.
What it means
Supports interferon as a disease-modifying option, especially for younger, low-risk people.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.